Search

Your search keyword '"A, Masson-Lecomte"' showing total 863 results
Start Over Author "A, Masson-Lecomte"
863 results on '"A, Masson-Lecomte"'

3. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H. Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R. M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Contieri, Roberto, Mertens, Laura S., Claps, Francesco, Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., Kiemeney, Lambertus A. L. M., Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N’Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas W. G.

Published
2024
Full Text
View/download PDF

8. Patients non répondeurs au BCG

Author

Leon, Priscilla, Pradère, Benjamin, Neuzillet, Yann, Bajeot, Anne Sophie, Marcq, Gautier, Prost, Doriane, Thibault, Constance, Xylinas, Evanguelos, Allory, Yves, Audenet, François, Masson-Lecomte, Alexandra, Seisen, Thomas, Rouprêt, Morgan, and Roumiguié, Mathieu

Published
2024
Full Text
View/download PDF

9. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels

Author

Mertens, Laura S., Bruins, Harman Maxim, Contieri, Roberto, Babjuk, Marek, Rai, Bhavan P., Puig, Albert Carrión, Escrig, Jose Luis Dominguez, Gontero, Paolo, van der Heijden, Antoine G., Liedberg, Fredrik, Martini, Alberto, Masson-Lecomte, Alexandra, Meijer, Richard P., Mostafid, Hugh, Neuzillet, Yann, Pradere, Benjamin, Redlef, John, van Rhijn, Bas W.G., Rouanne, Matthieu, Rouprêt, Morgan, Sæbjørnsen, Sæbjørn, Seisen, Thomas, Shariat, Shahrokh F., Soria, Francesco, Soukup, Viktor, Thalmann, George, Xylinas, Evanguelos, Mariappan, Paramananthan, and Alfred Witjes, J.

Published
2024
Full Text
View/download PDF

13. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

Author

Irene J. Beijert, Liang Cheng, Fredrik Liedberg, Karin Plass, Sean R. Williamson, Paolo Gontero, Maria J. Ribal, Marko Babjuk, Peter C. Black, Ashish M. Kamat, Ferran Algaba, David M. Berman, Arndt Hartmann, Alexandra Masson-Lecomte, Morgan Rouprêt, Antonio Lopez-Beltran, Hemamali Samaratunga, Shahrokh F. Shariat, A. Hugh Mostafid, Murali Varma, Steven Shen, Maximilian Burger, Toyonori Tsuzuki, Joan Palou, Eva M. Compérat, Richard J. Sylvester, Theo H. van der Kwast, Bas W.G. van Rhijn, and Michelle R. Downes

Subjects
Bladder, Cancer, Grading, Survey, European Association of Urology, International Society of Urological Pathology, Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary urothelial neoplasm of low malignant potential [PUNLMP], low-grade [LG], high-grade [HG] carcinoma) are used. Objective: To ask the European Association of Urology (EAU) and International Society of Urological Pathology (ISUP) members regarding their current practice and preferences of grading systems. Design, setting, and participants: A web-based, anonymous questionnaire with ten questions on grading of NMIBC was created. The members of EAU and ISUP were invited to complete an online survey by the end of 2021. Thirteen experts had previously answered the same questions. Outcome measurements and statistical analysis: The submitted answers from 214 ISUP members, 191 EAU members, and 13 experts were analyzed. Results and limitations: Currently, 53% use only the WHO2004 system and 40% use both systems. According to most respondents, PUNLMP is a rare diagnosis with management similar to Ta-LG carcinoma. The majority (72%) would consider reverting back to WHO1973 if grading criteria were more detailed. Separate reporting of WHO1973-G3 within WHO2004-HG would influence clinical decisions for Ta and/or T1 tumors according the majority (55%). Most respondents preferred a two-tier (41%) or a three-tier (41%) grading system. The current WHO2004 grading system is supported by a minority (20%), whereas nearly half (48%) supported a hybrid three- or four-tier grading system composed of both WHO1973 and WHO2004. The survey results of the experts were comparable with ISUP and EAU respondents. Conclusions: Both the WHO1973 and the WHO2004 grading system are still widely used. Even though opinions on the future of bladder cancer grading were strongly divided, there was limited support for WHO1973 and WHO2004 in their current formats, while the hybrid (three-tier) grading system with LG, HG-G2, and HG-G3 as categories could be considered the most promising alternative. Patient summary: Grading of non–muscle-invasive bladder cancer (NMIBC) is a matter of ongoing debate and lacks international consensus. We surveyed urologists and pathologists of European Association of Urology and International Society of Urological Pathology on their preferences regarding NMIBC grading to generate a multidisciplinary dialogue. Both the “old” World Health Organization (WHO) 1973 and the “new” WHO2004 grading schemes are still used widely. However, continuation of both the WHO1973 and the WHO2004 system showed limited support, while a hybrid grading system composed of both the WHO1973 and the WHO2004 classification system may be considered a promising alternative.

Published
2023
Full Text
View/download PDF

16. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures

Author

Fontugne, Jacqueline, Xylinas, Evanguelos, Krucker, Clémentine, Dixon, Victoria, Groeneveld, Clarice S., Pinar, Ugo, Califano, Gianluigi, Bucau, Margot, Verine, Jérôme, Desgrandchamps, François, Hermieu, Jean-François, Radvanyi, François, Allory, Yves, and Masson-Lecomte, Alexandra

Published
2023
Full Text
View/download PDF

17. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies

Author

Laura S. Mertens, Vidit Sharma, Surena F. Matin, Stephen A. Boorjian, R. Houston Thompson, Bas W.G. van Rhijn, and Alexandra Masson-Lecomte

Subjects
Urothelial cancer, Upper tract, Bladder recurrence, Nephroureterectomy, Ureterorenoscopy, Intravesical instillation, Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Context: Bladder recurrences have been reported in 22–47% of patients after surgery for upper urinary tract urothelial carcinoma (UTUC). This collaborative review focuses on risk factors for and treatment strategies to reduce bladder recurrences after upper tract surgery for UTUC. Objective: To review the current evidence on risk factors and treatment strategies for intravesical recurrence (IVR) after upper tract surgery for UTUC. Evidence acquisition: This collaborative review is based on a literature search of PubMed/Medline, Embase, Cochrane Library, and currently available guidelines on UTUC. Relevant papers on bladder recurrence (etiology, risk factors, and management) after upper tract surgery were selected. Special attention has been paid to (1) the genetic background of bladder recurrences, (2) bladder recurrences after ureterorenoscopy (URS) with or without a biopsy, and (3) postoperative or adjuvant intravesical instillations. The literature search was performed in September 2022. Evidence synthesis: Recent evidence supports the hypothesis that bladder recurrences after upper tract surgery for UTUC are often clonally related. Clinicopathologic risk factors (patient, tumor, and treatment related) have been identified for bladder recurrences after UTUC diagnosis. Specifically, the use of diagnostic ureteroscopy before radical nephroureterectomy (RNU) is associated with an increased risk of bladder recurrences. Further, a recent retrospective study suggests that performing a biopsy during ureteroscopy may further worsen IVR (no URS: 15.0%; URS without biopsy: 18.4%; URS with biopsy: 21.9%). Meanwhile, a single postoperative instillation of intravesical chemotherapy has been shown to be associated with a reduced bladder recurrence risk after RNU compared with no instillation (hazard ratio 0.51, 95% confidence interval 0.32–0.82). Currently, there are no data on the value of a single postoperative intravesical instillation after ureteroscopy. Conclusions: Although based on limited retrospective data, performing URS seems to be associated with a higher risk of bladder recurrences. Future studies are warranted to assess the influence of other surgical factors as well as the role of URS biopsy or immediate postoperative intravesical chemotherapy after URS for UTUC. Patient summary: In this paper, we review recent findings on bladder recurrences after upper tract surgery for upper urinary tract urothelial carcinoma.

Published
2023
Full Text
View/download PDF

19. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Author

Rouprêt, Morgan, Seisen, Thomas, Birtle, Alison J., Capoun, Otakar, Compérat, Eva M., Dominguez-Escrig, José L., Gürses Andersson, Irene, Liedberg, Fredrik, Mariappan, Paramananthan, Hugh Mostafid, A., Pradere, Benjamin, van Rhijn, Bas W.G., Shariat, Shahrokh F., Rai, Bhavan P., Soria, Francesco, Soukup, Viktor, Wood, Robbert G., Xylinas, Evanguelos N., Masson-Lecomte, Alexandra, and Gontero, Paolo

Published
2023
Full Text
View/download PDF

20. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

Author

Beijert, Irene J., Cheng, Liang, Liedberg, Fredrik, Plass, Karin, Williamson, Sean R., Gontero, Paolo, Ribal, Maria J., Babjuk, Marko, Black, Peter C., Kamat, Ashish M., Algaba, Ferran, Berman, David M., Hartmann, Arndt, Masson-Lecomte, Alexandra, Rouprêt, Morgan, Lopez-Beltran, Antonio, Samaratunga, Hemamali, Shariat, Shahrokh F., Mostafid, A. Hugh, Varma, Murali, Shen, Steven, Burger, Maximilian, Tsuzuki, Toyonori, Palou, Joan, Compérat, Eva M., Sylvester, Richard J., van der Kwast, Theo H., van Rhijn, Bas W.G., and Downes, Michelle R.

Published
2023
Full Text
View/download PDF

22. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H. Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R.M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S., Claps, Francesco, Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., Kiemeney, Lambertus A.L.M., Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N'Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas.W.G.

Published
2023
Full Text
View/download PDF

24. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration

Author

Lonati , Chiara, Afferi, Luca, Mari, Andrea, Minervini, Andrea, Krajewski, Wojciech, Borghesi, Marco, Schulz, Gerald B., Rink, Michael, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Martini, Alberto, Necchi, Andrea, Contieri, Roberto, Hurle, Rodolfo, Umari, Paolo, Zamboni, Stefania, Simeone, Claudio, Soria, Francesco, Marra, Giancarlo, Gontero, Paolo, Teoh, Jeremy Yuen-Chun, Klatte, Tobias, Bajeot, Anne-Sophie, Roumiguié, Mathieu, Rouprêt, Morgan, Masson-Lecomte, Alexandra, Laukhtina, Ekaterina, Valiquette, Anne Sophie, Mir, M. Carmen, Antonelli, Alessandro, Einerhand, Sarah M. H., Hendricksen, Kees, Carando, Roberto, Fankhauser, Christian D., Baumeister, Philipp, Mattei, Agostino, Shariat, Shahrokh F., and Moschini, Marco

Published
2022
Full Text
View/download PDF

25. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Maxim Bruins, H., Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R.M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S., Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., A.L.M. Kiemeney, Lambertus, Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N'Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas.W.G.

Published
2022
Full Text
View/download PDF

29. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration

Author

Lonati, Chiara, Baumeister, Philipp, Afferi, Luca, Mari, Andrea, Minervini, Andrea, Krajewski, Wojciech, Azizi, Sosan, Hendricksen, Kees, Martini, Alberto, Necchi, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Tafuri, Alessandro, Antonelli, Alessandro, Cerruto, Maria Angela, Rouprêt, Morgan, Masson-Lecomte, Alexandra, Laukhtina, Ekaterina, D’Andrea, David, Shariat, Shahrokh F., Soria, Francesco, Marra, Giancarlo, Gontero, Paolo, Contieri, Roberto, Hurle, Rodolfo, Valiquette, Anne Sophie, Mir, M. Carmen, Zamboni, Stefania, Simeone, Claudio, Klatte, Tobias, Teoh, Jeremy Yuen-Chun, Yoshida, Soichiro, Fujii, Yasuhisa, Carando, Roberto, Schulz, Gerald B., Mordasini, Livio, Mattei, Agostino, and Moschini, Marco

Published
2022
Full Text
View/download PDF

31. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)

Author

Leon, P., Saint, F., Audenet, F., Roumiguié, M., Allory, Y., Loriot, Y., Masson-Lecomte, A., Pradère, B., Seisen, T., Traxer, O., Xylinas, E., Roupret, M., and Neuzillet, Y.

Published
2022
Full Text
View/download PDF

35. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment

Author

Roumiguié, Mathieu, Compérat, Eva, Chaltiel, Léonor, Nouhaud, François Xavier, Verhoest, Gregory, Masson-Lecomte, Alexandra, Colin, Pierre, Audenet, François, Houédé, Nadine, Larré, Stéphane, Xylinas, Evanguelos, Brunelle, Serge, Piana-Thomassin, Jeanne, Cotte, Juliette, Pignot, Géraldine, Neuzillet, Yann, and Rouprêt, Morgan

Published
2021
Full Text
View/download PDF

36. Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

Author

Mertens, L.S., primary, Bruins, H.M., additional, Contieri, R., additional, Babjuk, M., additional, Bhavan, R., additional, Carrion Puig, A., additional, Dominguez Escrig, J.L., additional, Gontero, P., additional, Van Der Heijden, A.G., additional, Liedberg, F., additional, Mariappan, P., additional, Masson-Lecomte, A., additional, Meijer, R.P., additional, Mostafid, H., additional, Neuzillet, Y., additional, Pradere, B., additional, Van Rhijn, B.W.G., additional, Roupret, M., additional, Seisen, T., additional, Soria, F., additional, Viktor, S., additional, Thalmann, G., additional, Xylinas, E., additional, and Witjes, F., additional

Published
2024
Full Text
View/download PDF

37. Individual patient data validation of the definitions of BCG failure in patients with non-muscle invasive urothelial carcinoma of the bladder: An international multi-centre retrospective study

Author

Gontero, P., primary, Soria, F., additional, Babjuk, M., additional, Burger, M., additional, Comperat, E., additional, Mostafid, H., additional, Palou Redorta, J., additional, Roupret, M., additional, Van Rhijn, B.W., additional, Zigeuner, R., additional, Shariat, S.F., additional, Cohen, D., additional, Masson-Lecomte, A., additional, Xylinas, E., additional, Mariappan, P., additional, Rai, B.P., additional, Capoun, O., additional, Soukup, V., additional, Thalmann, G., additional, Pradere, B., additional, Seisen, T., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, and Sylvester, R.J., additional

Published
2024
Full Text
View/download PDF

38. Towards defining follow-up strategies for patients with primary (first diagnosis) EAU2021 intermediate-risk non-muscle invasive bladder cancer

Author

Contieri, R., primary, Beijert, I., additional, Martini, A., additional, Camperat, E.M., additional, Hernandez, V., additional, Bruins, H.M., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, Masson-Lecomte, A., additional, Cohen, D., additional, Mostafid, H., additional, Shariat, S.F., additional, Roupret, M., additional, Pradere, B., additional, Zigeuner, R., additional, Soria, F., additional, Soukup, V., additional, Palou Redorta, J., additional, Capoun, O., additional, Burger, M., additional, Gontero, P., additional, Sylvester, R., additional, Mertens, L., additional, and Van Rhijn, B.W.G., additional

Published
2024
Full Text
View/download PDF

45. Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies

Author

Leonard Lugand, Guillaume Mestrallet, Rebecca Laboureur, Clement Dumont, Fatiha Bouhidel, Malika Djouadou, Alexandra Masson-Lecomte, Francois Desgrandchamps, Stephane Culine, Edgardo D. Carosella, Nathalie Rouas-Freiss, and Joel LeMaoult

Subjects
spheroid, renal cell carcinoma, immune checkpoint inhibitors, standardization, PD-1, heterogeneity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Tumor spheroids play an increasingly important role in cancer research. Their ability to recapitulate crucial features of tumor biology that are lost in the classically used 2D models along with their relative simplicity and handiness have made them the most studied 3D tumor model. Their application as a theranostic tool or as a means to study tumor-host interaction is now well-established in various cancers. However, their use in the field of Renal Cell Carcinoma (RCC) remains very limited. The aim of this work is to present methods to implement a basic RCC spheroid model. These methods cover the steps from RCC tumor dissociation to spheroid infiltration by immune cells. We present a protocol for RCC dissociation using Liberase TM and introduce a culture medium containing Epithelial Growth Factor and Hydrocortisone allowing for faster growth of RCC primary cells. We show that the liquid overlay technique allows for the formation of spheroids from cell lines and from primary cultures. We present a method using morphological criteria to select a homogeneous spheroid population based on a Fiji macro. We then show that spheroids can be infiltrated by PBMCs after activation with OKT3 or IL-15. Finally, we provide an example of application by implementing an immune spheroid killing assay allowing observing increased spheroid destruction after treatment with PD-1 inhibitors. Thus the straightforward methods presented here allow for efficient spheroid formation for a simple RCC 3D model that can be standardized and infused with immune cells to study immunotherapies.

Published
2022
Full Text
View/download PDF

47. Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study

Author

Tristan Delory, Annabelle Goujon, Alexandra Masson-Lecomte, Pauline Arias, Anthony Laurancon-Fretar, Béatrice Bercot, Pierre Mongiat-Artus, Jean-Michel Molina, and Matthieu Lafaurie

Subjects
Fosfomycin, Fluoroquinolones, Prophylaxis, Prostate Biopsy, Cohort study, Infectious and parasitic diseases, RC109-216
Abstract

Objectives: The increasing incidence of fluoroquinolones (FQ) resistance may lower its efficacy in preventing UTI following transrectal ultrasound-guided prostate biopsy (TRUS-PB). We assessed the efficacy and safety of FQ and fosfomycin-trometamol (FT) in patients undergoing TRUS-PB. Methods: A prospective observational study was conducted between April 2017 and June 2019 and enrolled men undergoing TRUS-PB and receiving a single-dose of FQ (FQ-arm) or FT (FT-arm) for UTI prophylaxis per physician’s choice. The primary efficacy endpoint was self-reported TRUS-PB UTI. We assessed baseline factors associated with UTI with logistic regression. Results: A total of 222 men were enrolled, 141/222 (64%) received FQ, and 81/222 (36%) FT. The median age was 67.6 years [IQR, 61.4–72.1] and the Charlson score was 3 [IQR, 3–5]. The overall incidence of self-reported TRUS-PB UTI was 12% (24/197, (95%CI, 8%–17%)): 15% (17/116, (95% CI, 10%–17%)) in FQ-arm, versus 9% (7/81, 95% CI (5%–13%)) in FT-arm (RR = 0.55 (95% CI, 0.22–1.40), p-value = 0.209). No baseline characteristic was significantly associated with TRUS-PB UTI. Safety was similar between the arms: the rate of the reported adverse event was 31% (36/116, (95% CI, 25%–37%) in the FQ-arm versus 36% (28/81, (95% CI, 28%–41%)) in the FT-arm (RR = 1.17 (95% CI, 0.64–2.15), p = 0.602). Conclusions: TRUS-PB UTI prophylaxis with FT and FQ has similar efficacy and safety. A randomized comparison of these two antibiotics is warranted.

Published
2021
Full Text
View/download PDF

50. Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database

Author

Pignot, G., primary, Baboudjian, M., additional, Masson-Lecomte, A., additional, Lebacle, C., additional, Tillou, X., additional, Waeckel, T., additional, Duperron, C., additional, Monges, A., additional, Alezra, E., additional, Irani, J., additional, Lechevallier, E., additional, Gravis, G., additional, and Walz, J., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results